Previous 10 | Next 10 |
MENLO PARK, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and extend healthy lifespan, announced today that it has appointed Steven B. Engle as its ...
Gainers: Aquantia (NYSE: AQ ) +36% . Sinclair Broadcast (NASDAQ: SBGI ) +28% . Athenex (NASDAQ: ATNX ) +25% . Bridgeline Digital (NASDAQ: BLIN ) +22% . Regulus Therapeutics (NASDAQ: RGLS ) +18% . Ovid Therapeutics (NASDAQ: OVID ) +17% . Daxor Corporation (NYSEMKT: DXR ) +17% ....
Thinly traded micro cap CohBar ( CWBR +27.1% ) is up on a 4x surge in volume, albeit on turnover of only 268K shares, in reaction to the resumption of a Phase 1a/1b study evaluating lead drug CB4211, in development for the potential treatment of nonalcoholic steatohepatitis (NASH) and ob...
MENLO PARK, Calif., May 03, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and extend healthy lifespan, today announced that it has concluded its recent discussions ...
MENLO PARK, Calif., April 26, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the company will release its first quarter 2019 financial res...
Call to feature thought leaders discussing mitochondria and mitochondrial-drived peptides as a potential source of novel therapeutics Call and webcast scheduled for May 2, 2019; 10:30-11:45am EDT MENLO PARK, Calif., April 23, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. ...
MENLO PARK, Calif., April 22, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and extend healthy lifespan, today announced the appointment of David Greenwood to its B...
Introduction CohBar Inc. ( CWBR ) is a small cap ($137M) clinical stage biotechnology company, founded in 2007 by Drs. Amatruda, Barzilai, and Cohen. CohBar's scientific forte is in the research and development of mitochondria-based therapeutics (MBTs) that offers the potential to address ...
CohBar Inc. (CWBR) Q4 2018 Earnings Conference Call March 18, 2019 17:00 ET Company Participants Glenn Garmont - Investor Relations Philippe Calais - Interim Chief Executive Officer Ken Cundy - Chief Scientific Officer Jeff Biunno - Chief Financial Officer Conference Call Pa...
CohBar (NASDAQ: CWBR ): Q4 GAAP EPS of -$0.10. More news on: CohBar, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
3D Systems Corporation (DDD) is expected to report $-0.11 for Q1 2024 ZW Data Action Technologies Inc. (CNET) is expected to report for Q1 2024 Celularity Inc. (CELU) is expected to report for Q1 2023 DMK Pharmaceuticals Corporation (DMKPQ) is expected to report for Q1 2024 Atlant...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...